Zomedica Corp.
ZOM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.06 | 1.00 | 0.27 |
| FCF Yield | -25.87% | -10.51% | -7.95% | -5.05% |
| EV / EBITDA | -2.84 | -6.33 | -8.74 | -5.09 |
| Quality | ||||
| ROIC | -25.41% | -12.41% | -7.05% | -6.85% |
| Gross Margin | 69.95% | 68.76% | 72.12% | 73.89% |
| Cash Conversion Ratio | 0.50 | 0.46 | 0.69 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.96% | 82.65% | – | – |
| Free Cash Flow Growth | -47.53% | -62.42% | 14.22% | 8.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 0.35 | 1.67 | 9.89 |
| Interest Coverage | 0.00 | -180.53 | -21,923.00 | -3,530.56 |
| Efficiency | ||||
| Inventory Turnover | 1.62 | 1.54 | 1.92 | 0.38 |
| Cash Conversion Cycle | 180.39 | -86.21 | -237.36 | -59.93 |